Who are Rosiglitazone/alpha-lipoic acid's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rosiglitazone-alpha-lipoic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rosiglitazone/alpha-lipoic acid — Competitive Intelligence Brief

Rosiglitazone/alpha-lipoic acid (Rosiglitazone/alpha-lipoic acid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione + antioxidant combination. Area: Diabetes.

marketed Thiazolidinedione + antioxidant combination PPAR-γ (rosiglitazone); mitochondrial oxidative stress (alpha-lipoic acid) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Rosiglitazone/alpha-lipoic acid (Rosiglitazone/alpha-lipoic acid) — Seoul St. Mary's Hospital. Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while alpha-lipoic acid acts as an antioxidant to reduce oxidative stress and improve glucose metabolism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rosiglitazone/alpha-lipoic acid TARGET	Rosiglitazone/alpha-lipoic acid	Seoul St. Mary's Hospital	marketed	Thiazolidinedione + antioxidant combination	PPAR-γ (rosiglitazone); mitochondrial oxidative stress (alpha-lipoic acid)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione + antioxidant combination class)

Seoul St. Mary's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rosiglitazone/alpha-lipoic acid — Competitive Intelligence Brief. https://druglandscape.com/ci/rosiglitazone-alpha-lipoic-acid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab